• Treatment of chronic idiopathic constipation.

Contraindicated in:

• Hypersensitivity
• Intestinal perforation or obstruction, obstructive ileus, Crohn's disease, ulcerative colitis, or toxic megacolon/megarectum
• End-stage renal disease requiring dialysis.

Use Cautiously in:

• Depression
• Severe renal impairment (CCr <30 mL/min) (↓ dose)
• OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk
• Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant
• Pedi: Safety and effectiveness not established in children
• Geri: May need to ↓ dose in older adults due to age-related ↓ in renal function.

GI: abdominal pain, diarrhea, nausea, abdominal distension, flatulence, vomiting.

Neuro: headache, depression, dizziness, fatigue, SUICIDAL THOUGHTS/BEHAVIOR.

Drug-Drug:

• None reported.

• Tablets: 1 mg; 2 mg;

• PO (Adults): 2 mg once daily.

Motegrity

• Acts as a selective serotonin type 4 (5-HT₄) receptor agonist, which stimulates colonic peristalsis and leads to increased bowel motility.

• Increased frequency of complete spontaneous bowel movements.

Therapeutic Classification: prokinetic agents

Pharmacologic Classification: five ht4 agonists

Absorption: >90% absorbed following oral administration.

Distribution: Extensively distributed to tissues.

Metabolism/Excretion: Primarily excreted by the kidneys, with 60–65% being excreted unchanged in the urine, and 5% in feces.

Half-life: 24 hr.

Resotran

(plasma concentrations)

• Instruct patient to take prucalopride as directed. Advise patient to read Patient Information before starting therapy and with each Rx refill in case of changes.
• Advise patient and family members to discontinue prucalopride and notify health care professional immediately if suicidal ideation and behavior (unusual changes in mood or behavior, persistent worsening of depression, feeling sad or hopeless, thoughts or attempts at self harm, emergence of suicidal thoughts or behavior) occur.
• Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
• Rep: Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected, or if breastfeeding. Inform patient of pregnancy exposure registry that monitors pregnancy outcomes in women exposed to prucalopride during pregnancy. Register patients by contacting MotherToBaby Pregnancy Studies conducted by the Organization of Teratology Information Specialists at 1-877-311-8972 or visiting mothertobaby.org/pregnancy-studies/.

proo-KAL-oh-pride

NDC Code^*

• 54092- Shire US Manufacturing Inc.
  • 54092-546- MOTEGRITY
    • 54092-546-01- 30 TABLET, FILM COATED in 1 BOTTLE (54092-546-01)

• 54092- Shire US Manufacturing Inc.
  • 54092-547- MOTEGRITY
    • 54092-547-01- 30 TABLET, FILM COATED in 1 BOTTLE (54092-547-01)

• 54092- Shire US Manufacturing Inc.
  • 54092-547- MOTEGRITY
    • 54092-547-02- 1 BOTTLE in 1 CARTON (54092-547-02) > 7 TABLET, FILM COATED in 1 BOTTLE

• 54092- Shire US Manufacturing Inc.
  • 54092-547- MOTEGRITY
    • 54092-547-03- 1 BOTTLE in 1 CARTON (54092-547-03) > 30 TABLET, FILM COATED in 1 BOTTLE